EMSAM
LOE Approachingselegiline
NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
EMSAM (selegiline) is monoamine oxidase inhibitors [moa]. First approved in 2006.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMSAM is a transdermal monoamine oxidase inhibitor (MAOI) approved in 2006 for depression. It delivers selegiline through a patch formulation, bypassing first-pass metabolism to enable lower systemic doses and improved tolerability compared to oral MAOIs. The drug works by inhibiting monoamine oxidase enzyme, increasing dopamine, norepinephrine, and serotonin in the central nervous system.
$12MPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($12M, 5,360 claims in 2023), this product faces significant generic erosion and operates on a small, niche commercial team focused on retention rather than growth.
Mechanism of Action
Monoamine Oxidase Inhibitors
Pharmacologic Class:
Monoamine Oxidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Started Mar 2007
77 enrolled
Parkinson's Disease
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
127 enrolled
Cognition DisordersHIV Infections
Career Relevance
Working on EMSAM offers limited career growth due to its small market presence ($12M in Part D spending), approaching LOE, and zero linked job postings. This is a niche, mature product suitable for professionals seeking stability and deep expertise in MAOI therapy rather than scaling commercial operations.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.